

*Cardiorenal Differences Among NSAIDs and Coxibs:
Real-World Experience*

This supplement to *The American Journal of Managed Care* contains information on the cardiorenal differences among NSAIDs and Coxibs. The supplement has been peer reviewed by an expert in the field.

Chair

Edmund H. Sonnenblick, MD
Professor
Division of Cardiology
Weiller Hospital of the
Albert Einstein College of Medicine
Bronx, New York

Faculty

Thomas A. Burke, PharmD, MPH
Director, Global Health Outcomes
Pharmacia Corporation
Peapack, New Jersey

Scott C. Henderson, MS
Senior Manager, Statistical
Methodology
IMS Health
Plymouth Meeting, Pennsylvania

Fleur H. Lee, MPH
Research Associate
Pfizer Inc
Pfizer Pharmaceutical Group
Outcomes Research
New York, New York

Jeffrey D. Miller, MS
Director
Pfizer Inc
New York, New York

Dan Pettitt, DVM, MSc
Director
Pfizer Inc
New York, New York

Mason W. Russell, MAPE
Vice President and Director
Healthcare Research Group
Comprehensive Neuroscience, Inc.
Waltham, Massachusetts

Gurkirpal Singh, MD
Director, ARAIS-PMS Program
Stanford University School
of Medicine
Palo Alto, California

Heather von Allmen
Director of Custom Research
IMS Consulting
Plymouth Meeting, Pennsylvania

Andrew Whelton, MD, PhD
Professor of Medicine
Universal Clinical Research
Center, Inc
The Johns Hopkins University
School of Medicine
Baltimore, Maryland

Sean Z. Zhao, MD, PhD
Director, Global Health Outcomes
Pharmacia Corporation
Peapack, New Jersey

DISCLOSURE STATEMENT

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants have declared the following affiliations with corporate organizations:

- **Jeffrey D. Miller, MS**
Research Grant Support From:
Pfizer Inc
- **Heather von Allmen, BA**
Consultant To:
Pharmacia/Pfizer
- **Mason W. Russell, MAPE**
Research Grant Support From:
Pharmacia/Pfizer
- **Andrew Whelton, MD, PhD**
Research Grant Support From/
Consultant To:
Pharmacia/Pfizer
GlaxoSmithKline
Merck
- **Gurkirpal Singh, MD**
Research Support From:
Pharmacia/Pfizer
Boehringer Ingelheim
- **Edmund H. Sonnenblick, MD**
Advisor To:
Solvay

These participants are employees of Pharmacia Corporation:

- **Thomas A. Burke, PharmD**
- **Sean Z. Zhao, MD, PhD**

These participants are employees of Pfizer Inc:

- **Fleur H. Lee, MPH**
- **Dan Pettitt, DVM, MSC**

This participant declares no financial arrangement or affiliation with any corporate organizations:

- **Scott C. Henderson, MS**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

The Next Era of Anticoagulation Therapy

GOAL

To provide current information on anticoagulation therapy for the treatment of atrial fibrillation.

TARGET AUDIENCE

This activity is intended for physicians, medical directors, pharmacists, pharmacy directors, P&T committee members, primary care physicians, and specialists in hematology and internal medicine.

EDUCATIONAL OBJECTIVES

After participating in this activity, participants should be better able to:

- Explain the epidemiology and initial management of new-onset atrial fibrillation.
- Discuss the randomized trial evidence for the efficacy and safety of anticoagulants.
- Describe the impact of anticoagulation therapy on costs, stroke risk, and quality of life.
- Identify the new antithrombotic drugs currently under study and review their impact on treating atrial fibrillation.

CONTINUING MEDICAL EDUCATION ACCREDITATION

The University of Pennsylvania School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The University of Pennsylvania School of Medicine designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits he/she spends in the activity.

This enduring material was released in April 2004, and the CME certification will expire on April 30, 2005.

FUNDING

This program is supported by an unrestricted educational grant from **AstraZeneca**.